Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Schlabach MR"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Schlabach MR, Lin S, Collester ZR, Wrocklage C, Shenker S, Calnan C, Xu T, Gannon HS, Williams LJ, Thompson F, Dunbar PR, LaMothe RA, Garrett TE, Colletti N, Hohmann AF, Tubo NJ, Bullock CP, Le Mercier I, Sofjan K, Merkin JJ, Keegan S, Kryukov GV, Dugopolski C, Stegmeier F, Wong K, Sharp FA, Cadzow L, Benson MJ
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2023 Dec 15; Vol. 133 (24). Date of Electronic Publication: 2023 Dec 15.
Autor:
Liu H; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Golji J; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Brodeur LK; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Chung FS; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Chen JT; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., deBeaumont RS; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Bullock CP; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Jones MD; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Kerr G; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Li L; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Rakiec DP; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Schlabach MR; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Sovath S; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Growney JD; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Pagliarini RA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Ruddy DA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., MacIsaac KD; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., Korn JM; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA., McDonald ER 3rd; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA, USA. rob.mcdonald@novartis.com.
Publikováno v:
Nature medicine [Nat Med] 2019 Jan; Vol. 25 (1), pp. 95-102. Date of Electronic Publication: 2018 Dec 17.
Publikováno v:
Genes & development [Genes Dev] 2017 Nov 15; Vol. 31 (22), pp. 2310.
Autor:
Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC
Publikováno v:
ELife [Elife] 2017 Oct 31; Vol. 6. Date of Electronic Publication: 2017 Oct 31.
Autor:
Mazzucco AE; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA., Smogorzewska A; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.; The Rockefeller University, New York, New York 10065, USA., Kang C; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; School of Biological Sciences, Seoul National University, Seoul 08826, South Korea., Luo J; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA., Schlabach MR; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.; KSQ Pharmaceuticals, Cambridge, Massachusetts 02139, USA., Xu Q; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA., Patel R; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA., Elledge SJ; Howard Hughes Medical Institute, Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Publikováno v:
Genes & development [Genes Dev] 2017 Oct 01; Vol. 31 (19), pp. 1933-1938.
Autor:
McDonald ER 3rd; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA. Electronic address: rob.mcdonald@novartis.com., de Weck A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Schlabach MR; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Billy E; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Mavrakis KJ; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Hoffman GR; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Belur D; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Castelletti D; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Frias E; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Gampa K; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Golji J; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Kao I; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Li L; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Megel P; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Perkins TA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Ramadan N; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Ruddy DA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Silver SJ; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Sovath S; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Stump M; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Weber O; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Widmer R; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Yu J; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Yu K; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Yue Y; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Abramowski D; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Ackley E; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Barrett R; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Berger J; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Bernard JL; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Billig R; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Brachmann SM; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Buxton F; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Caothien R; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Caushi JX; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Chung FS; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Cortés-Cros M; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., deBeaumont RS; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Delaunay C; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Desplat A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Duong W; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Dwoske DA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Eldridge RS; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Farsidjani A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Feng F; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Feng J; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Flemming D; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Forrester W; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Galli GG; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Gao Z; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Gauter F; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Gibaja V; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Haas K; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Hattenberger M; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Hood T; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Hurov KE; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Jagani Z; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Jenal M; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Johnson JA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Jones MD; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Kapoor A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Korn J; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Liu J; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Liu Q; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Liu S; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Liu Y; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Loo AT; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Macchi KJ; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Martin T; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., McAllister G; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Meyer A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Mollé S; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Pagliarini RA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Phadke T; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Repko B; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Schouwey T; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Shanahan F; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Shen Q; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Stamm C; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Stephan C; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Stucke VM; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Tiedt R; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Varadarajan M; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Venkatesan K; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Vitari AC; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Wallroth M; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Weiler J; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Zhang J; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Mickanin C; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Myer VE; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Porter JA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Lai A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Bitter H; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Lees E; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Keen N; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Kauffmann A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Stegmeier F; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Hofmann F; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA., Schmelzle T; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA. Electronic address: tobias.schmelzle@novartis.com., Sellers WR; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA.
Publikováno v:
Cell [Cell] 2017 Jul 27; Vol. 170 (3), pp. 577-592.e10.
Autor:
Krall EB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.; Broad Institute of Harvard and MIT, Cambridge, United States.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States., Wang B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.; Broad Institute of Harvard and MIT, Cambridge, United States.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States., Munoz DM; Oncology Disease Area, Novartis Institute for Biomedical Research, Cambridge, United States., Ilic N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.; Broad Institute of Harvard and MIT, Cambridge, United States.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States., Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.; Broad Institute of Harvard and MIT, Cambridge, United States.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States., Niederst MJ; Oncology Disease Area, Novartis Institute for Biomedical Research, Cambridge, United States., Yu K; Oncology Disease Area, Novartis Institute for Biomedical Research, Cambridge, United States., Ruddy DA; Oncology Disease Area, Novartis Institute for Biomedical Research, Cambridge, United States., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.; Broad Institute of Harvard and MIT, Cambridge, United States.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States., Kim JW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.; Broad Institute of Harvard and MIT, Cambridge, United States.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States., Redig AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States., Gainor JF; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States., Williams JA; Oncology Disease Area, Novartis Institute for Biomedical Research, Cambridge, United States., Asara JM; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States., Doench JG; Broad Institute of Harvard and MIT, Cambridge, United States., Janne PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States., Shaw AT; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States., McDonald Iii RE; Oncology Disease Area, Novartis Institute for Biomedical Research, Cambridge, United States., Engelman JA; Oncology Disease Area, Novartis Institute for Biomedical Research, Cambridge, United States., Stegmeier F; Oncology Disease Area, Novartis Institute for Biomedical Research, Cambridge, United States., Schlabach MR; Oncology Disease Area, Novartis Institute for Biomedical Research, Cambridge, United States., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.; Broad Institute of Harvard and MIT, Cambridge, United States.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States.
Publikováno v:
ELife [Elife] 2017 Feb 01; Vol. 6. Date of Electronic Publication: 2017 Feb 01.
Autor:
Munoz DM; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Cassiani PJ; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Li L; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Billy E; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland., Korn JM; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Jones MD; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Golji J; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Ruddy DA; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Yu K; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., McAllister G; Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., DeWeck A; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland., Abramowski D; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland., Wan J; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Shirley MD; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Neshat SY; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Rakiec D; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., de Beaumont R; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Weber O; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland., Kauffmann A; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland., McDonald ER 3rd; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Keen N; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Hofmann F; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland., Sellers WR; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Schmelzle T; Oncology Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland., Stegmeier F; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Schlabach MR; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts. mschlabach@ksqtx.com.
Publikováno v:
Cancer discovery [Cancer Discov] 2016 Aug; Vol. 6 (8), pp. 900-13. Date of Electronic Publication: 2016 Jun 03.